Zura Bio reports Q3 2025 net loss of $20.0M; cash $139M to fund through 2027

Zura Bio Ltd

2025-Q3 EPS reported -$0.57

Net loss $20.0M ($0.21/sh) vs $22.9M ($0.26/sh) in Q3 2024; R&D spend rose to $11.9M as Phase 2 trials advanced.
Cash and equivalents $139.0M as of Sep 30, 2025; company expects to fund planned operations through 2027.
Phase 2 trials tibulizumab: TibuSHIELD (HS) topline Q3 2026; TibuSURE (SSc) topline Q4 2026.
G&A expenses decreased to $7.6M from $13.3M, driven by prior-year one-time non-cash share-based comp.
No revenue reported; clinical-stage immunology company with no approved products.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.